The largest database of trusted experimental protocols

16 protocols using atglistatin

1

Preparation of DAG+FFA and Inhibitor Solutions

Check if the same lab product or an alternative is used in the 5 most similar protocols
1,3-Dilinoleoyl-rac-glycerol (Sigma, D9508) was dissolved in fresh dimethyl sulfoxide (DMSO) for stock solution at 50 mM (or 50 mg/ml for the in vivo study). Similarly, oleic acid (Sigma, O1008) was dissolved in fresh DMSO to 50 mM (or 50 mg/ml for the in vivo study). 1,3-Dilinoleoyl-rac-glycerol and oleic acid were mixed at a 1:1 ratio to prepare the DAG+FFA mixture. Working solution was added with pre-set DAG and FFA concentrations by mixing common serum-free medium proportionately. Final concentrations were set at 8 μM, 16 μM and 32 μM. Atglistatin (Sigma, SML1075) was dissolved in DMSO for stock solution at 10 mM. Final working concentrations of 40 μM Atglistatin was used in all experiments. Nutlin-3a(Sigma, SML0580) was dissolved in DMSO for stock solution at 5 mg/ml. Final working concentrations of 10 μM Nutlin-3a was used in experiments.
+ Open protocol
+ Expand
2

Seipin Depletion and Lipid Metabolism in OLN-93 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
OLN-93 cells (termed OLN cells) were cultured in high glucose DMEM (Gibco, Grand Island, USA, Cat# 11965092) supplemented with 10% fetal bovine serum (Gibco, Auckland, New Zealand, Cat# 10099141 C) at 37 °C in 10% CO2. After overnight attachment, cells were cultured with serum-free EBSS media and carried on experiments 8 h or 24 h after induction. For depletion of Seipin, OLN cells were transfected with Seipin-short hairpin RNA (sh-Seipin, HANBio, 5’-3’ sense, GCC AAU GUC UCG CUG ACU ATT; 3’-5’ antisense, UAG UCA GCG AGA CAU UGG CTT) for 72 h, or vehicle control short hairpin RNA (NC, 5’-3’ sense, UUC UCC GAA CGU GUC ACG UTT; 3’-5’ antisense, ATG UGA CAC GUU CGG AGA ATT). For LDs induction, OLN cells were supplemented with 0.5 μM Oleic acid (OA; Sigma-Aldrich, Vienna, Austria, Cat# O1383) in 100% ethanol for 16 h. For regulating lipid metabolism, sh-Seipin cells were treated with 1 μM RG for 24 h. For Atglistatin treatment, cells were treated with 25 μM Atglistatin (Sigma-Aldrich, Natick, Massachusetts, US, Cat# SML1075) stock solution for 24 h at the beginning of differentiation.
+ Open protocol
+ Expand
3

Modulating Lipid Droplet Formation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The combination of iDGAT (DGAT 1 inhibitor: A922500; DGAT2 inhibitor: PF‐06424439), ATGL inhibitor atglistatin (SML1075; Sigma‐Aldrich Chemie GmbH) as well as MAGL inhibitor MJN110 (SML0872; Sigma‐Aldrich) served to block the LD formation. Bone marrow‐derived myeloid cells were cultured with the indicated FFA in the presence of variant inhibitors for 7 days.
+ Open protocol
+ Expand
4

Assay of Atglistatin Effects

Check if the same lab product or an alternative is used in the 5 most similar protocols
Red C12 experimental methods were performed similar to what was described previously (Rambold et al., 2015 (link)). Atglistatin (Sigma) was added, where indicated, at 10uM concentration for the duration of assay. Images were taken using the Zeiss 710 Confocal Microscope.
+ Open protocol
+ Expand
5

Atglistatin Treatment for Metabolic Disorders

Check if the same lab product or an alternative is used in the 5 most similar protocols
Atglistatin (Atg, Sigma‐Aldrich) was suspended in 0.5% DMSO in PBS as described previously.32 After 5‐months ND and HFD feeding, mice were randomly assigned into: (1) Atg treatment group with i.p. injection at a dose of 100 μmol/kg body weight; (2) vehicle (Veh) control group with i.p. injection of 0.5% DMSO in PBS using the same volume; (3) control group without any treatment. Both Atg and veh treatment were performed 8 h before PMs harvesting.32
+ Open protocol
+ Expand
6

Assay of Atglistatin Effects

Check if the same lab product or an alternative is used in the 5 most similar protocols
Red C12 experimental methods were performed similar to what was described previously (Rambold et al., 2015 (link)). Atglistatin (Sigma) was added, where indicated, at 10uM concentration for the duration of assay. Images were taken using the Zeiss 710 Confocal Microscope.
+ Open protocol
+ Expand
7

Zebrafish Metabolic Modulation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tg(-3.5ubb:plin2-tdTomato) zebrafish were outcrossed with caspers to generate the F2 or F3 generation. F2 or F3 fish were raised at a standard density of 50 fish per 6.0 l tank. For drug treatment, fish were removed from the system at 21 dpf and placed at a density of one fish per well in a six-well plate with 10 ml of E3 per well. To evaluate viability, fish were treated for 24 hr and quantified for live and dead larvae. After a 24 hr incubation with the drug, fish were anesthetized with Tricaine and imaged using the described protocol to quantify (1) standard length and (2) area of PLIN2-tdTOMATO expression corresponding to visceral adipose tissue area. Fish were treated with Forskolin (Sigma-Aldrich, St. Louis, USA; catalog #F6886), Auranofin (Sigma-Aldrich, St. Louis, USA; catalog #A6733), JS-K (Sigma-Aldrich, St. Louis, USA; catalog #J4137), or Atglistatin (Sigma-Aldrich, St. Louis, USA; catalog #SML1075[1]), which were all dissolved in DMSO.
+ Open protocol
+ Expand
8

Photoreceptor Survival Promotion by PEDF Peptides

Check if the same lab product or an alternative is used in the 5 most similar protocols
PEDF and its derived peptides, 17-mer, 44-mer, and 34-mer were diluted in HBSS and aliquots were added to the cultures at 10 nM final concentration 48 hr after seeding the cells. The 17-mer and 44-mer peptides from the neurotrophic domain were the effectors and the 34-mer peptide from the antiangiogenic domain of PEDF was used as a negative control. For suppressing the effects of PEDF and its derived peptides, a fragment of the ligand-binding site of PEDF-R, the P1 blocking peptide, diluted in HBSS was added at a P1-PEDF molar ratio of 10:1. Alternatively, a selective inhibitor of PEDF-R, Atglistatin (Sigma, SML1075) at a 3.5 μM concentration (aliquoted and diluted in DMSO) was used. Both blocking peptide and inhibitor were preincubated in the cultures for 1 hr before adding the effectors. Preliminary experiments with 10 nM and 100 nM PEDF showed that 10 nM PEDF was the optimum PEDF concentration to promote survival of photoreceptors. The reported affinity of the PEDF/PEDF-R interactions is within this value (Kd of ~3 –10 nM PEDF) and the concentration of 10 nM PEDF has been used in assays with other cells such as R28 cells, which efficacy is blocked with 10-fold molar excess of P1 peptide or in the presence of 3.5 μM Atglistatin (Kenealey et al., 2015 (link); Notari et al., 2006 (link); Subramanian et al., 2013 (link)).
+ Open protocol
+ Expand
9

Hep3B Cell Culture Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
The human hepatocellular carcinoma cell line Hep3B was derived from American Tissue Culture Collection (Manassas, VA, USA) and cultured in minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), in the presence of appropriate antibiotics and antimycotics (Biological Industries; Kibbutz Beit-Haemek, Israel). The cultures were maintained at a 37 °C, 5% CO2, humidified atmosphere. Atglistatin, GW6471, and GW9662 (Sigma-Aldrich; St. Louis, MO, USA) were dissolved in DMSO and added to the culture at concentrations indicated. The cells treated with the same volume of DMSO (no more than 0.1%) served as controls. Transfection with small interfering RNA (siRNA) was performed by incubating the cells with the siRNA mixture using GenMute siRNA Transfection Reagent (SignaGen Laboratories; Rockville, MD, USA) (final concentrations: 20 nM) according to manufacturer’s instructions for 6 h before switching to fresh culture media.
+ Open protocol
+ Expand
10

Activated Macrophage Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
BMDMs were treated with LPS from E. coli (O55:B5; L6529; Sigma-Aldrich) and flagellin from Salmonella typhimurium (Sigma-Aldrich) at a concentration of 100 ng/mL, Pam3CysK4 (L2000; EMC Microcollections) at a concentration of 5 µg/mL, poly:IC (Sigma-Aldrich) at a concentration of 20 µg/mL, and Zymosan from Saccharomyces cerevisiae (Sigma-Aldrich) at a concentration of 100 µg/mL. Zymosan was opsonized to increase uptake by phagocytosis and sonicated just before use. Atglistatin (SML1075; Sigma-Aldrich) was used at a concentration of 20 μM, and cells were pretreated for 1 h before further treatment. C75 (C5490; Sigma-Aldrich) was used at a concentration of 5 µg/mL, and cells were pretreated for 1 h before further treatment. Indomethacin (I7378; Sigma-Aldrich) was used at 10 µM and NS-398 (N194; Sigma-Aldrich) was used at 1 µM, and cells were pretreated for 1 h before further treatment. PGE2 (2296; Tocris, Bio-Techne) was added at 0.1 µM 1 h after treatment with LPS.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!